Colorectal Cancer Metastatic Clinical Trial
— RePERSOOfficial title:
Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib
Regorafenib has demonstrated a significant benefit in overall survival in metastatic colorectal cancer (mCRC) patients. However, more than 50% of patients had severe adverse events (grade 3-4), leading to temporary or definitive discontinuation of treatment. The RePERSO study proposes to adapt the regorafenib dose regimen taking into account firstly the measurement of sum of metabolites M-2 and M-5 and secondly the occurrence of toxicity during treatment. This treatment personalization through therapeutic drug monitoring pharmacological dosing optimization strategy aims at validating the proof of concept of regorafenib therapeutic drug monitoring and at improving the benefit in OS in patients, using the previously defined Csum therapeutic range.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | May 2025 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - - Signed and dated informed consent - Male or female patients = 18 years-old at time of Informed Consent Form (ICF) signature - Patients must have a histologically proven metastatic colorectal cancer - Patients who have previously been treated with standard therapy including a fluoropyrimidine, oxaliplatin, irinotecan, an anti-VEGF (bevacizumab or aflibercept) and an anti-EGFR (cetuximab or panitumumab) for patients who had a RAS wild-type tumor - In mRCC with MSI-H, the patient must have received immunotherapy. For mRCC with BRAF mutation, the patient should have received a BRAF inhibitor if eligible. - Patients with a BRAF V600E mutation who have previously received treatment with a BRAF inhibitor. - ECOG PS = 0 or 1 - Imaging target greater than one cm must be visible on CT - Patients must have adequate bone marrow, renal, and hepatic function, as evidenced by the pre-therapeutic check-up performed within 7 days before regorafenib initiation: Normal organ functions as defined below : 1. Absolute neutrophil count = 1.3 Giga/L 2. Platelets > 100 Giga/L 3. Hemoglobin = 9 g/dL 4. Serum creatinine = 1.5 x ULN (Upper Limit of Normal) or Glomerular filtration rate (GFR) =30 ml/min/1.73m2 according to the modified Diet in Renal Disease (MDRD) or CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) abbreviated formula 5. AST and ALT =3 x ULN (=5.0 × ULN for patients with liver involvement of their cancer) 6. Total Bilirubin =2 X ULN 7. Alkaline phosphatase =3 x ULN (=5 x ULN in patient with liver involvement of their cancer and/or with bone metastases). If Alkaline phosphatase > 3 ULN (or >5 ULN in patient with liver involvement of their cancer and/or with bone metatstases), hepatic isoenzymes 5-nucleotidase or GGT tests must be performed; hepatic isoenzymes 5-nucleotidase must be within the normal range and/or GGT < 3 x ULN 8. No argument for acute pancreatitis within 3 months before the start of study medication 9. No proteinuria: = 1+ protein will require a 24-hour urine collection that must show total protein excretion <1000 mg/24 hours - INR/PTT =1.5 x ULN - Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. For patients treated with VKA, Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care - Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy - Women of childbearing potential must have a negative serum ß-HCG pregnancy test within 7 days prior randomization - Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures - Patients affiliated to the Social Security System Exclusion Criteria: - - Prior treatment with regorafenib, and with any prior antiangiogenic inhibitor except bevacizumab - Hypersensitivity to the active substance or to any of the excipients - Systemic cancer therapy with unfinished washout (in general 3 weeks except for example for capecitabin which has a 1 week washout) - Concomitant treatment with a cytochrome P450 3A4 (CYP3A4) inducer or inhibitor or UGT1A9 inhibitor - Patients unable to swallow oral medication - Digestive obstruction, chronic inflammatory bowel disease or any malabsorption condition - Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to inclusion, except for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria]) - Ongoing uncontrolled infection (viral, bacterial or fungal) - Known history of human immunodeficiency virus (HIV) infection, active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy - Breastfeeding - Uncontrolled hypertension (systolic blood pressure >140 mmHg or diastolic pressure >90 mmHg despite optimal medical management) - Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), within 6 months before the start of study medication - Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months) - Myocardial infarction less than 6 months before the start of study medication - Any hemorrhage or bleeding event = Grade 3, NCI-CTCAE v 5.0 within 4 weeks prior to the start of study medication - Major surgical procedure, open biopsy or significant traumatic injury within 28 days before start of study medication - Non-healing wound, ulcer or bone fracture - Unresolved toxicity higher than Grade 1, NCI-CTCAE v 5.0, attributed to any prior therapy/procedure excluding alopecia, anemia, hypothyroidism and oxaliplatin induced neuropathy - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule - Adults legally protected (judicial protection, guardianship or supervision), person deprived of their liberty |
Country | Name | City | State |
---|---|---|---|
France | CHU Brest | Brest | |
France | CHU Caen | Caen | |
France | AP-HP Henri Mondor | Créteil | |
France | Institut Daniel Hollard, Groupe Hospitalier Mutualiste de Grenoble | Grenoble | |
France | CHU Nantes | Nantes | |
France | AP-HP La Pitié-Salpétrière | Paris | |
France | AP-HP St Antoine | Paris | |
France | CHU Poitiers | Poitiers | |
France | Centre Eugène Marquis | Rennes | |
France | CHU Rennes | Rennes | |
France | CHU Rouen | Rouen | |
France | CHU Tours | Tours |
Lead Sponsor | Collaborator |
---|---|
Rennes University Hospital |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time from inclusion to death | Determine whether "optimal exposure" to regorafenib based on plasma concentration of the drug and its metabolites can improve overall survival in mCRC patients | 12 months | |
Secondary | Ten months survival rate | Percentage of patients alive 10 months after inclusion | 10 months | |
Secondary | Objective response Rate | Objective response Rate (ORR) defined as the rate of patients with complete or partial response | 12 months | |
Secondary | Disease Control Rate | Disease Control Rate (DCR) is defined as the rate of patients with complete response, partial response or stable disease, | 12 months | |
Secondary | Progression-free survival | Progression-free survival (PFS) is defined as the time from inclusion to date of first observed disease progression (radiological or clinical) or death due to any cause, if death occurs before progression is documented. The actual date that the tumor scan was performed will be used for this calculation. PFS for patients without disease progression or death at the time of analysis will be censored at the last date of tumor evaluation. | 12 months | |
Secondary | Severe toxicities | Percentage of patients with significant toxicities (= grade 3). Adverse events will be assessed from inclusion to 28 day after the discontinuation of the study drug and classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. | 12 months | |
Secondary | Percentage of optimal exposure | Percentage of patients with "optimal exposure" - i.e. with Csum at day 15 within the range [2.5 - 5.5 mg/L]) - at cycle 1 and cycle 2 | 2 months | |
Secondary | Difference in overall survival between patient with different metabolite 2 plasma ratio | Overall survival for the half of patients with a low ratio of plasma concentration of Metabolite 2 Cycle2/Ccyle1 compared to the overall survival for the half of patients with a high ratio of plasma concentration of Metabolite 2 Cycle2/Cycle1 | 2 months | |
Secondary | Genetic polymorphism impact | Genetic polymorphisms in gene involved in regorafenib metabolism and plasma concentrations of regorafenib and its metabolites | 12 months | |
Secondary | Body composition | Body composition will be determined on Computerized Tomography scan (CT-scan) imaging done at baseline and for tumor response evaluation during treatment. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03941080 -
Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
|
||
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Completed |
NCT03647839 -
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT05057052 -
Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis
|
Phase 2 | |
Terminated |
NCT02316496 -
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
|
Phase 2 | |
Completed |
NCT03251612 -
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02380443 -
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT02149784 -
Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients
|
Phase 3 | |
Recruiting |
NCT01959061 -
Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases
|
Phase 4 | |
Terminated |
NCT01668680 -
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
|
Phase 2 | |
Recruiting |
NCT05068531 -
Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
|
||
Not yet recruiting |
NCT04525807 -
Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
|
||
Completed |
NCT04482608 -
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
|
||
Recruiting |
NCT03193710 -
The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved
|
N/A | |
Recruiting |
NCT04854213 -
PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03144804 -
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT03142516 -
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
|
Phase 2 | |
Active, not recruiting |
NCT01910610 -
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
|
Phase 3 | |
Recruiting |
NCT05759728 -
A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
|
Phase 1/Phase 2 |